Skip to main content
Log in

Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Twenty-four healthy volunteers participated in a study on the disposition of ergotamine following oral and rectal administration. Plasma samples were collected surrounding each dose of medication and a new mass spectrometry method was used for quantitation of the samples. A mean peak plasma concentration of 454 pg/ml was measured an average of 50 min following a 2 mg rectal dose. In contrast, the 2 mg oral dose produced a mean peak plasma concentration of 21 pg/ml an average of 69 min following the dose. Area under the concentration time curve indicated a relative bioavailability of 5% for the oral dosage form. Conflicting data on ergotamine disposition highlight the factors which may be responsible for determining bioavailability and pharmacologic activities of the compound.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rall TW, Schleifer LS (1980) Oxytocin, prostaglandins, ergot alkaloids, and other agents. In: Gilman AG, Goodman LS, Gilman A (eds) The Pharmacologic basis of therapeutics, 6th edn. Macmillan, New York, pp 939–947

    Google Scholar 

  2. Robayo JR (1983) Vascular headache. In: Katcher BS, Young LY, Koda-Kimble MA (eds) Applied therapeutics. The clinical use of drugs, 3rd edn. Applied Therapeutics, San Francisco, pp 1105–7

    Google Scholar 

  3. Winholz M (ed, 1983) The Merck Index, 10th edn. Merck & Co., Inc., Rahway, p 3611

    Google Scholar 

  4. Kleimola TT (1978) Quantitative determination of ergot alkaloids in biological fluids by radioimmunoassay. Br J Clin Pharmacol 6: 255–260

    Google Scholar 

  5. Van Mansvelt FJW, Greving JE, De Zeelum RA (1978) Identification of ergot peptide alkaloids based on gas liquid chromatography of the peptide moiety. J Chromatogr 151: 113–120

    Google Scholar 

  6. Edlund PO (1981) Determination of ergot alkaloids in plasma by high-performance liquid chromatography and fluorescence detection. J Chromatogr 226: 107–115

    Google Scholar 

  7. Schran HF, Schwarz HJ, Talbot KC, Loeffler LJ (1979) Specific radioimmunoassay of ergot peptide alkaloids in plasma. Clin Chem 25: 1928–1933

    Google Scholar 

  8. Ala-Hurula V, Myllylae VV, Arvela P, Kaerki NT, Hokkanen E (1979) Systemic availability of ergotamine tartrate after three successive doses and during continuous medication. Eur J Clin Pharmacol 16: 355–60

    Google Scholar 

  9. Ibraheem JJ, Paalzow L, Tfelt-Hansen P (1983) Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br J Clin Pharmacol 16: 695–699

    Google Scholar 

  10. Haering N, Schubert R, Settlage JA, Sanders SW (1985) The measurement of ergotamine in human plasma by triple sector quadrupole mass spectrometry with negative ion chemical ionization. Biom Mass Spectrom 12: 197–199

    Google Scholar 

  11. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York

    Google Scholar 

  12. Aellig WH, Nuesch E (1977) Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man. Int J Clin Pharmacol 15: 106–112

    Google Scholar 

  13. Aellig WH (1984) Investigation of the venoconstrictor effect of 8'hydroxydihydroergotamine, the main metabolite of dihydroergotamine, in man. Eur J Clin Pharmacol 26: 239–242

    Google Scholar 

  14. Mueller-Schweinitzer E (1984) What is known about the action of dihydroergotamine on the vasculature in man? Int J Clin Pharmacol Ther Toxicol 22: 677–682

    Google Scholar 

  15. Semenowicz-Siuda K, Markeiwicz A, Korczynska-Wardecka J (1984) Cirdadian bioavailability and some effects of propranolol in healthy subjects and in liver cirrhosis. Int J Clin Pharmacol Ther Toxicol 12: 653–658

    Google Scholar 

  16. Hurwitz GA, Webb JG, Walle T, Bai SA, Daniell HB, Gourley L, Loadholt CB, Gaffney TE (1983) Exercise-induced increments in plasma levels of propranolol and noradrenaline. Br J Clin Pharmacol 16: 599–608

    Google Scholar 

  17. Melander A, McLean A (1983) Influence of food intake on presystemic clearance of drugs. Clin Pharmacokinet 8: 286–296

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sanders, S.W., Haering, N., Mosberg, H. et al. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol 30, 331–334 (1986). https://doi.org/10.1007/BF00541538

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00541538

Key words

Navigation